CFO
TXG icon

Callan Family Office’s 10x Genomics TXG Stock Holding History

Callan Family Office’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$462K Buy
12,059
+178
+1% +$4.67K 0.01% 845
2026
Q1 		$252K Sell
11,881
-2,416
-17% -$48.3K 0.01% 986
2025
Q4 		$233K Buy
+14,297
New +$216K 0.01% 1005

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Callan Family Office's TXG Position: Q2 2026 in Review

Callan Family Office increased its 10x Genomics (TXG) stake by 1.5% in Q2 2026, buying an estimated $4.67K and bringing the position to 12,059 shares worth $462K. The position accounts for 0.01% of the portfolio, ranked #845.

Callan Family Office first reported a position in TXG in Q4 2025 and has held it in 3 quarters since. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Callan Family Office held 12,059 shares of 10x Genomics worth $462K as of Q2 2026.
  • Callan Family Office bought 178 10x Genomics shares in Q2 2026, an estimated $4.67K.
  • 10x Genomics made up 0.01% of Callan Family Office's portfolio in Q2 2026, its #845 holding.
  • Callan Family Office first reported a position in 10x Genomics in Q4 2025 and has held it in 3 quarters since.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.